-
Mashup Score: 6ASCO 2024 – Blenrep “should return” to the US - 1 year(s) ago
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
Source: www.oncologypipeline.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 7
But will the FDA accept the surrogate endpoint used in ASC4First?
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: First #ASCO24 story: Scemblix could set new standard in front-line leukaemia $NVS via @ApexOnco https://t.co/MsRVXyeL6J
-
-
Mashup Score: 10CCR8 expectations - 1 year(s) ago
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: Is CCR8 the new Claudin18.2? @ApexOnco analysis of an I-O mechanism that's quietly become hot: https://t.co/TzuGyiWRGM $CH…
-
-
Mashup Score: 4
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: $BNTX sees pancreatic promise amid neoantigen delays https://t.co/MbQOCpREVZ #AACR24 $MRNA $GRTS $RHHBY
-
-
Mashup Score: 3AACR 2024 – Akeso impresses in stomach cancer - 1 year(s) ago
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: Akeso impresses in stomach cancer https://t.co/BHzKy6DAsE #AACR24 https://t.co/BCWAyqudkS
-
-
Mashup Score: 3J&J speeds into new bladder cancer trial - 1 year(s) ago
The company takes another project from Taris into phase 3 as it chases a $5bn market.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: $JNJ speeds into non-muscle invasive bladder cancer phase 3 with TAR-210, via @ApexOnco https://t.co/XbFVoaZaWX
-
-
Mashup Score: 6Time for Gilead to cut magrolimab loose - 1 year(s) ago
Another week, another magrolimab setback. The four remaining solid tumour trials of the Gilead anti-CD47 MAb that were formally still ongoing have now been placed on clinical hold by the FDA, according to a statement Gilead quietly slipped out last night. Last week the project’s key phase 3 AML trial Enhance-3 was discontinued, along with all work in haematology, after an increased risk of death…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: The slow death of magrolimab (part 94), via @ApexOnco -> https://t.co/1a7sygDzVd $GILD
-
-
Mashup Score: 5Revolution in the next KRAS battleground - 1 year(s) ago
With Revolution Medicines initiating dosing in the first-in-human study of its KRAS G12D inhibitor RMC-9805, the industry pipeline now comprises six clinical-stage projects with this modality. If the KRAS G12C space, now featuring the approved drugs Lumakras from Amgen and Krazati from Mirati, fast became crowded, then that targeting KRAS G12D-driven tumours might follow suit, given that G12D is…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ByMadeleineA: KRAS G12D is crowded! https://t.co/QFoSnRLSvD https://t.co/VxZHQncGo6
-
-
Mashup Score: 8The pullback from RET inhibition - 1 year(s) ago
Lilly’s disclosure today that it was discontinuing the next-generation RET inhibitor LOXO-260 points to the quiet biopharma exodus from this once-promising mechanism. On one hand Lilly’s Retevmo has grabbed the lion’s share of first-line RET-mutant NSCLC patients, with the Libretto-431 trial backing the registrational Libretto-001 study, an achievement that saw off one competitor: Roche pulled…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @JacobPlieth: $LLY discontinues LOXO-260, and the pullback from RET continues. Via @ApexOnco -> https://t.co/CT40b13sYW $BPMC $RHHBY $DS…
-
-
Mashup Score: 3Bristol shows its alnuctamab hand - 1 year(s) ago
With two BCMA-targeting T-cell-engager bispecifics already boasting US accelerated approvals, and a third seeking a similar nod, how can others compete? Bristol Myers Squibb and AbbVie haven’t said they would pursue the accelerated pathway for alnuctamab and ABBV-383 respectively, and both are now in formal phase 3 trials. The unveiling of alnuctamab’s phase 3 Alumminate study has revealed that…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet-
RT @ApexOnco: $BMY shows its alnuctamab hand https://t.co/Y4x8YRtToI
-
RT @JacobPlieth: $GSK Blenrep “should return” to the US, #ASCO24 hears. Via @ApexOnco -> https://t.co/4tdvJ0aIVC $JNJ $BMY $PFE $TSVT $LEGN…